trending Market Intelligence /marketintelligence/en/news-insights/trending/fvd5hoskozvwlqjl_yv_rq2 content esgSubNav
In This List

Kiniksa Pharmaceuticals closes $152.6M IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Kiniksa Pharmaceuticals closes $152.6M IPO

Kiniksa Pharmaceuticals Ltd. closed its IPO of 8,477,777 class A common shares at $18 apiece with gross proceeds of $152.6 million.

The company also granted the underwriters an option to buy up to 1,271,666 additional shares.

All of the shares were offered by Bermuda-based Kiniksa, which develops treatments for debilitating diseases with significant unmet medical need.

The shares started trading on the Nasdaq Global Select Market on May 24, under the ticker symbol KNSA.

Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC acted as joint book-running managers for the offering, with JMP Securities LLC and Wedbush Securities Inc. as co-managers.